Biological mechanisms of glioma invasion and potential therapeutic targets

Journal of Neuro-Oncology

Volumn 53, Issue 2, 2001, Pages 129-147

  Tysnes, B B ^a   Mahesparan, R ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Anti invasive therapy; Biological mechanisms; Experimental models; Glioma invasion; Invasive phenotype; Therapeutic targets

Indexed keywords

CELL ADHESION MOLECULE; CELL RECEPTOR; CYTOKINE; GROWTH FACTOR; ISIS 3521; LOVOSTATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE C; PROTEINASE; RAS PROTEIN; TAMOXIFEN; THROMBOXANE SYNTHASE; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL MODEL; CANCER INVASION; CELL INTERACTION; CELL MIGRATION; CHEMICAL CARCINOGENESIS; CLINICAL TRIAL; CYTOSKELETON; DNA MICROARRAY; DRUG TARGETING; ENZYME INHIBITION; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE THERAPY; GENETIC ANALYSIS; GENETIC MODEL; GLIOMA; HUMAN; IN VITRO STUDY; MEDICAL GENETICS; METABOLIC REGULATION; NONHUMAN; ONCOGENE; PATHOGENESIS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TISSUE CHARACTERIZATION; TUMOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL ADHESION MOLECULES; CELL MOVEMENT; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 10; CYTOSKELETON; DISEASE PROGRESSION; ENDOPEPTIDASES; EXTRACELLULAR MATRIX; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLIOBLASTOMA; GLIOMA; GROWTH SUBSTANCES; HUMANS; INTEGRINS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PHOSPHORIC MONOESTER HYDROLASES; PROTEASE INHIBITORS; PTEN PHOSPHOHYDROLASE; THROMBOXANE-A SYNTHASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0034761808     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012249216117     Document Type: Review

References (206)

1. Tumours of central neuroepithelial origin
2. Leptomeningeal tissue: A barrier against brain tumor cell invasion
3. Tumor cell invasion and angiogenesis in the central nervous system
4. Migratory pattern of fetal rat brain cells and human glioma cells in the adult rat brain
5. Brain tumor cell invasion, anatomical and biological considerations
6. Gene amplification in malignant human gliomas: Clinical and histopathologic aspects
7. Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma
8. Clonal genomic alterations in glioma malignancy stages
9. Molecular genetic characterization of CNS tumor oncogenesis
10. Genetics and malignant progression of human brain tumours
11. Genetic alterations associated with glioma progression
12. Genetic alterations associated with the evolution and progression of astrocytic brain tumours
13. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades
14. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors
15. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
16. Identification of a candidate tumour suppressor gene. MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
17. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme
18. Subsets of glioblastoma multiforme defined by molecular genetic analysis
19. Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins
20. Interrelationship between Schwann cell function and extracellular matrix production
21. The extracellular matrix of the nervous system
22. Tumoral invasion in the central nervous system
23. The role of integrins in the malignant phenotype of gliomas
24. The extracellular matrix of the central and peripheral nervous systems: Structure and function
25. Immunohistochemical localization of hyaluronic acid in rat and human brain
26. Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumour stroma
27. Stimulation of extracellular matrix components in the normal brain by invading glioma cells
28. Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies
29. Role of high molecular weight extracellular matrix proteins in glioma cell migration
30. ECM dependent and integrin mediated tumor cell migration of human glioma and melanoma cell lines under serum-free conditions
31. Adhesion and migration of human glioma cells are differently dependent on extracellular matrix molecules
32. The role of extracellular matrix in human astrocytoma migration and proliferation studied in a microliter scale assay
33. Determinants of human astrocytoma migration
34. Extracellular matrix proteins inhibit proliferation, upregulate migration and induce morphological changes in human glioma cell lines
35. Extracellular matrix-induced cell migration from glioblastoma biopsy specimens in vitro
36. Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin
37. Fibronectin-mediated cell migration promotes glioma cell invasion through chemokinetic activity
38. Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: Clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues
39. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells
40. Tenascin expression in astrocytomas correlates with angiogenesis
41. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro
42. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death
43. Laminin expression by glial fibrillary acidic protein positive cells in human gliomas
44. Molecular profile of reactive astrocytes - Implications for their role in neurologic disease
45. Tumor invasion, proteolysis, and angiogenesis
46. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
47. Proteolysis and invasiveness of brain tumors: Role of urokinase-type plasminogen activator receptor
48. Extracellular matrix-degrading proteinases in the nervous system
49. Tumor cell interactions with the extracellular matrix during invasion and metastasis
50. Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed
51. Proteases and their inhibitors in human brain tumours: A review
52. Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas
53. Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors
54. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors
55. Matrix metalloproteinases and tissue inhibitor of metalloproteinases: A review of their role in tumorigenesis and tissue invasion
56. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
57. Mechanisms of glioma invasion: Role of matrix-metalloproteinases
58. The urokinase/urokinase-receptor system and cancer invasion
59. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors
60. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo
61. Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo
62. Cathepsin B expression and localization in glioma progression and invasion
63. Immunolocalization of cathepsin B in human glioma: Implications for tumor invasion and angiogenesis
64. Overexpression and localization of cathepsin B during the progression of human gliomas
65. Cathepsin B expression in human tumors
66. Changing views of the role of matrix metalloproteinase in metastasis
67. Integrins: Versatility, modulation, and signalling in cell adhesion
68. Signaling by integrin receptors
69. Characterization of integrin receptors in normal and neoplastic human brain
70. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue
71. Brain extracellular matrix, adhesion molecules, and glioma invasion
72. Integrin alpha3beta1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells
73. Towards a structural model of an integrin
74. Integrins and health
75. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2
76. Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors
77. Signal transduction by cell adhesion receptors
78. Expression and role of cadherins in astrocytic tumors
79. Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors
80. Migratory, invasive and metastatic capacity of NCAM transfected rat glioma cells
81. Transfection of glioma cells with the neural-cell adhesion molecule NCAM: Effect on glioma-cell invasion and growth in vivo
82. Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma
83. Paucity of retinoic acid receptor alpha (RAR alpha) nuclear immunostaining in gliomas and inability of retinoic acid to influence neural cell adhesion molecule (NCAM) expression
84. Differential expression of the CD44 molecule in human brain tumours
85. CD44 mediates human glioma cell adhesion and invasion in vitro
86. The normal structure and function of CD44 and its role in neoplasia
87. Signal transduction pathways and their relevance in human astrocytomas
88. Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro
89. Effects of growth factors on a human glioma cell line during invasion into rat brain aggregates in culture
90. Effects of EGF, bFGF, NGF and PDGF (bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro
91. Heterogeneous response to the growth factors (EGF, PDGF (bb), TGF-a, bFGF, IL-2) on glioma spheroid growth, migration and invasion
92. Domains of laminin with growth-factor activity
93. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas
94. Growth factor regulation of integrin-mediated cell motility
95. Signal transduction by integrins and its role in the regulation of tumor growth
96. Extracellular matrix and integrin signalling: The shape of things to come
97. Integrin-linked kinase (ILK): A regulator of integrin and growth-factor signalling
98. Recent insights into the role of integrins in cancer metastasis
99. Assessment of brain tumor cell motility in vivo and in vitro
100. Tumor cell invasion and gap junctional communication. I. Normal and malignant cells confronted in monolayer cultures
101. Tumor cell invasion and gap junctional communication. II. Normal and malignant cells confronted in multicell spheroids
102. Invasive glioma cells in tissue cultures
103. A rapid in vitro assay for quantitating the invasive potential of tumor cells
104. Invasion of rat neurogenic cell lines in embryonic chick heart fragments in vitro
105. Glioma cell interactions with fetal rat brain aggregates in vitro and with brain tissue in vivo
106. Invasiveness of human and animal cells into three-dimensional human optic nerve cultures
107. A novel model of glioma cell invasion using organotypic brain slice culture
108. Tracking the invasiveness of human astrocytoma cells by using green fluorescent protein in an organotypical brain slice model
109. Patterns of antigenic expression of human glioma cells
110. Modal DNA content of human intracranial neoplasms studied by flow cytometry
111. Collagens, integrins and the mesenchymal drift in glioblastomas: A comparison of biopsy specimens, spheroids and early monolayer cultures
112. Correlation of DNA ploidy and morphological features of human glioma cell cultures with the establishment of cell lines
113. Multicellular tumor spheroids from human gliomas maintained in organ culture
114. Long-term culture of organotypic multicellular glioma spheroids: A good culture model for studying gliomas
115. Animal models for brain tumors: Historical perspectives and future directions
116. Rat brain tumor models in experimental neurooncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas
117. Cancerogenic effects of methyl- and ethyl-nitrosourea (MNU and ENU) at single intracerebral and intracarotidal injection in newborn and young BD-rats
118. Experimental tumours of the nervous system
119. Tumours of the nervous system
120. Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture
121. Development of experimental models for meningeal neoplasia using intrathecal injection of 9L gliosarcoma and Walker 256 carcinosarcoma in the rat
122. Phenotypic properties of neoplastic cell lines developed from fetal rat brain cells in culture after exposure to ethylnitrosourea in vivo
123. A mouse model of glioma: Biology, pathology, and therapeutic opportunities
124. Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo
125. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
126. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice
127. A model for xenotransplantation of human malignant astrocytomas into the brain of normal adult rats
128. Growth of precultured human glioma specimens in nude rat brain
129. Diffuse brain invasion of glioma cells requires beta 1 integrins
130. Migration arrest in glioma cells is dependent on the alphav integrin subunit
131. Role of integrins in cancer: Survey of expression patterns
132. Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns
133. Basement membrane invasion of glioma cells mediated by integrin receptors
134. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results
135. Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: Kinetics and implications for diagnosis and therapy
136. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody
137. Preparation and characterization of anti-tenascin monoclonal antibody - Streptavidin conjugates for pretargeting applications
138. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6
139. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model
140. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin
141. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study
142. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma - Phase I and II study
143. Expression of tissue inhibitors of metalloproteinases: Negative regulators of human glioblastoma invasion in vivo
144. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas
145. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors
146. Transfection of an invasive human astrocytoma cell line with a TIMP-1 cDNA: Modulation of astrocytoma invasive potential
147. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro
148. Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors
149. Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells
150. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth
151. The cytoskeleton and brain tumour cell migration
152. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro
153. In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate
154. 10nm filaments in normal and transformed cells
155. Differential effects of vincristine and phenytoin on the proliferation, migration, and invasion of human glioma cell lines
156. Combined effect of alkyl-lysophospholipid and vincristine on proliferation, migration and invasion in human glioma cell lines in vitro
157. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro
158. Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C
159. The role of protein kinase C in migration of rat glioma cells from spheroid cultures
160. Signal tranduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway
161. Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor
162. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
163. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
164. Antisense oligonucleotides: An evolving technology for the modulation of gene expression in human disease
165. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood
166. Inhibition of protein kinase C by tamoxifen
167. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment
168. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: Preliminary results in a series of 'failed' patients
169. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen
170. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro
171. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen
172. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas
173. Proliferation of human malignant astrocytomas is dependent on Ras activation
174. Signal transduction by Ras-like GTPase: A potential target for anticancer ddrugs
175. Proteins of the Ras pathway as novel potential anticancer therapeutic targets
176. The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas
177. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects
178. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells
179. Gene therapy for brain tumors
180. Viral vectors for gene therapy
181. Current status of viral gene therapy for brain tumours
182. Replication-competent herpes simplex viral vectors for cancer therapy
183. Replicative adenoviruses for cancer therapy
184. From the cover: Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas
185. Neural stem cells are uniquely suited for cell replacement and gene therapy in the CNS
186. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas
187. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
188. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas
189. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway
190. PTEN gene and integrin signaling in cancer
191. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN
192. Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase
193. Thromboxane synthase regulates the migratory phenotype of human glioma cells
194. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
195. Differential display. A general protocol
196. Serial analysis of gene expression
197. Essay: Amersham Pharmacia Biotech & Science prize. Tantalizing transcriptomes - SAGE and its use in global gene expression analysis
198. A public database for gene expression in human cancers
199. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
200. Genome-wide analysis of DNA copy-number changes using cDNA microarrays
201. Systematic variation in gene expression patterns in human cancer cell lines
202. Guilt-by-association goes global
203. Proteomics: New perspectives, new biomedical opportunities
204. Proteomics: A new approach to the study of disease